Genuity Science’s approach combines high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis’ proprietary antisense technology, has the potential to significantly expedite the drug development process through a more direct translation of targets into therapeutics.
Under terms of the multi-year collaboration, Genuity Science will receive a combination of upfront payments and development milestones, plus product royalties.
“Ionis’ financial strength and the success of our validated antisense technology have positioned us to invest in new technologies that enhance our R&D capabilities,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “The collaboration with Genuity Science gives us the potential to significantly increase our discovery opportunities and better understand the complexities of human diseases based on genetics.”
“We are excited to collaborate with an innovative company like Ionis,” said Rob Brainin, chief executive officer of Genuity
The MarketWatch News Department was not involved in the creation of this content.
Sep 28, 2020 (TS Newswire via Comtex) —
KD Market Insights has published a report on global Pain Therapeutics market research report. The report offers valuable market insights drivers which would aid the industry leaders to develop and line up their market strategies supported by reliable and accurate data. According to KD Market Insights report, the global Pain Therapeutics market is expected to grow at a CAGR of XX.X% during the forecast period i.e. 2020-2025. The market was held to USD XX.X Million in 2019 and is projected to reach to a valuation of USD XX.X Million in 2025. The report covers a detailed chapter on market segmentation of Pain Therapeutics market covering market segments By Drug Class, By Indication and By Distribution Channel.
The report offers an exhaustive analysis of the market trends, opportunities, growth